WO2005097819A1 - D-homo-17-chlor-16(17)en steroide - Google Patents
D-homo-17-chlor-16(17)en steroide Download PDFInfo
- Publication number
- WO2005097819A1 WO2005097819A1 PCT/EP2005/003792 EP2005003792W WO2005097819A1 WO 2005097819 A1 WO2005097819 A1 WO 2005097819A1 EP 2005003792 W EP2005003792 W EP 2005003792W WO 2005097819 A1 WO2005097819 A1 WO 2005097819A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxy
- chloro
- dien
- homo
- group
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title claims abstract description 36
- 150000001875 compounds Chemical class 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 45
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 40
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 40
- -1 keto, methylene, difluoromethylene group Chemical group 0.000 claims description 39
- 229910052731 fluorine Inorganic materials 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 229910052801 chlorine Inorganic materials 0.000 claims description 13
- 125000004122 cyclic group Chemical group 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 230000003637 steroidlike Effects 0.000 claims description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 8
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 239000011737 fluorine Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 6
- 125000002560 nitrile group Chemical group 0.000 claims description 6
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 5
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000002577 pseudohalo group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000001730 thiiranyl group Chemical group 0.000 claims description 4
- RHMXJSWKQJYEOA-VXNCWWDNSA-N (8r,9s,13s,14s)-3,3-dimethoxy-13-methyl-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1C[C@@H]2C(CCC(C3)(OC)OC)=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C RHMXJSWKQJYEOA-VXNCWWDNSA-N 0.000 claims description 3
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 claims description 3
- 125000004423 acyloxy group Chemical group 0.000 claims description 3
- PFBUKDPBVNJDEW-UHFFFAOYSA-N dichlorocarbene Chemical class Cl[C]Cl PFBUKDPBVNJDEW-UHFFFAOYSA-N 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- QGXBDMJGAMFCBF-LUJOEAJASA-N epiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-LUJOEAJASA-N 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- SIJBDWPVNAYVGY-UHFFFAOYSA-N 2,2-dimethyl-1,3-dioxolane Chemical compound CC1(C)OCCO1 SIJBDWPVNAYVGY-UHFFFAOYSA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 206010058359 Hypogonadism Diseases 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000005997 bromomethyl group Chemical group 0.000 claims description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 230000035558 fertility Effects 0.000 claims description 2
- 238000002657 hormone replacement therapy Methods 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000000466 oxiranyl group Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000001548 androgenic effect Effects 0.000 abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
- 239000000243 solution Substances 0.000 description 38
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 229910052739 hydrogen Inorganic materials 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 239000000741 silica gel Substances 0.000 description 16
- 229910002027 silica gel Inorganic materials 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 238000000746 purification Methods 0.000 description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000004593 Epoxy Substances 0.000 description 5
- 239000000700 radioactive tracer Substances 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000005051 trimethylchlorosilane Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102000001307 androgen receptors Human genes 0.000 description 3
- 108010080146 androgen receptors Proteins 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- HSJPMRKMPBAUAU-UHFFFAOYSA-N cerium(3+);trinitrate Chemical compound [Ce+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O HSJPMRKMPBAUAU-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- SAQSTQBVENFSKT-UHFFFAOYSA-M TCA-sodium Chemical compound [Na+].[O-]C(=O)C(Cl)(Cl)Cl SAQSTQBVENFSKT-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- NWFNSTOSIVLCJA-UHFFFAOYSA-L copper;diacetate;hydrate Chemical compound O.[Cu+2].CC([O-])=O.CC([O-])=O NWFNSTOSIVLCJA-UHFFFAOYSA-L 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000004540 pour-on Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- QTVYUZHZWRAGFS-GBPMOCDDSA-N (8R,9R,10S,13S,14S)-13-ethyl-1,2,3,4,5,6,7,8,9,10,11,12,14,15,16,17-hexadecahydrocyclopenta[a]phenanthrene Chemical class C1CC2CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(CC)CC2 QTVYUZHZWRAGFS-GBPMOCDDSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 0 CCC1[C@](*)(CC)C(*)(*)C(N)=CC1 Chemical compound CCC1[C@](*)(CC)C(*)(*)C(N)=CC1 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 102100034067 Dehydrogenase/reductase SDR family member 11 Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical group ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005248 alkyl aryloxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 150000001441 androstanes Chemical class 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000003418 antiprogestin Substances 0.000 description 1
- 230000002054 antogonadotrophic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- GRXPVLPQNMUNNX-MHJRRCNVSA-N estrane Chemical compound C1CC2CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 GRXPVLPQNMUNNX-MHJRRCNVSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- NSBNSZAXNUGWDJ-UHFFFAOYSA-O monopyridin-1-ium tribromide Chemical compound Br[Br-]Br.C1=CC=[NH+]C=C1 NSBNSZAXNUGWDJ-UHFFFAOYSA-O 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- 229950011008 tetrachloroethylene Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical group COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Definitions
- the invention relates to D-homo-17-chloro-16 (17) -en steroids of the general formula I.
- WO 99/46279 discloses D-homo-16-chloro-17-oxosteroids which inhibit the 17 ⁇ -hydroxysteroid dehydrogenase.
- DE 19712488 discloses sulfamates of D-homostratrienes which, however, are unsubstituted on the 17a carbon.
- D-homo-17a-chloro-16 (17) -en steroids show antiandrogenic activity (EP 52799).
- D-Homo ⁇ 17a-substituted-Pregnane- and androstanes, in which the 16 (17) double bond is absent, are known from DE 2700267. Such compounds have an anesthetic effect.
- D-homo-11 ⁇ -aryl-17-chloro-16 (17) -en steroids are known from the prior art which are strong antigestagens (DE 4042005, Steroids, 1994, 59, 176-80). Also known is 17ass-hydroxy-7 ⁇ -methyl-D-homoestra-4,16-dien-3-one, which has androgenic and antigonadotropic properties (Steroids, 1990, 55, 59-64).
- D-homo-17-chloro-16 (17) -en steroids of the androstane, 19-norandrostane and 13-ethylgonane series are not yet known.
- the object of the present invention is therefore to provide new compounds with androgenic activity.
- R 1 for a C 6 alkyl group
- R 2 for a hydroxy group, C- ⁇ - 10 alkyloxy-, C ⁇ - 15 -acyloxy-, C 6 - ⁇ 5 -cycloalkylacyloxy-, C 7 -i 5 -arylacyloxy-, C 7 . 15 arylalkyloxy or a C 7 .
- R 3 for a hydroxyl group, C 10 alkyloxy, C 1 5 acyloxy, C 6 5 cycloalkylacyloxy, C. 15 aryl acyloxy, C 7 . 15 arylalkyloxy or a C 7 - ⁇ 5 alkylaryloxy group,
- R 2 and R 3 together represent a keto, methylene, difluoromethylene group or form a spirooxirane or a 2,2-dimethyl-1,3-dioxolane, including the 17a-C atom,
- STEROID stands for a steroidal partial ring system of the formulas A, B, C, D E and F, which are listed below,
- R 6 represents a hydrogen atom, a halogen atom, a hydroxyl group, a methyl group or a trifluoromethyl group
- X and Z each represent a hydrogen atom or together an oxygen atom or a hydroxyimino group
- R 7 is a hydrogen atom, a d- 6 alkyl group or a C- ⁇ - 6 alkenyl group
- R 8 is a hydrogen atom, a halogen atom, together with R 9 is a double bond
- R 9 represents a hydrogen atom, a hydroxyl group, a halogen atom, a methyl or ethyl group or together with R 8 a double bond,
- R 10 represents a hydrogen atom, a methyl group, a nitrile group, a hydroxymethylene or formyl group,
- R 11 represents a hydrogen atom, a methyl group, a nitrile group
- R 10 and R 11 in addition to the meanings given above, together form a double bond or a methylene bridge
- R 12 is a hydrogen atom or together with R 6 a double bond
- R 13 and R 14 together represent a double bond, an oxirane ring, a thiirane ring, a [2,3c] oxadiazole, a [3,2c] isoxazole or a [3,2c] pyrazole ring, and Y is an oxygen or nitrogen atom .
- the meandering lines on R 6 , R 7 , R 8 , R 11 , R 12 , R 13 , R 14 mean that these substituents can be ⁇ - or ⁇ -permanent.
- the compounds according to the invention have androgenic activity.
- the C 6 alkyl group is a branched or unbranched alkyl radical which, for example, by a methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl or tert-butyl group, n- Pentyl, i-pentyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl group is formed.
- halogen atom stands for a fluorine, chlorine, bromine or iodine atom.
- R 1 preferably denotes a methyl group or an ethyl group, the methyl group being particularly preferred.
- R 2 preferably denotes a hydroxyl or esterified hydroxyl group, in particular a formyloxy group, acetyloxy group, propanoyloxy group, butyryloxy group, [(trans-4-butylcyclohexyl) carbony] oxy group, phenylpropanoyloxy group, iso-butyryloxy group or undecanoyloxy group.
- R 3 preferably denotes a hydrogen atom, a methyl, ethyl, ethynyl, hydroxymethyl, chloromethyl, bromomethyl, cyanomethyl, azidomethyl, rhodanomethyl, methoxymethyl group.
- R 6 preferably denotes a hydrogen atom, an F, Cl, Br atom, a hydroxyl group, a methyl group or a trifluoromethyl group, X and Z preferably together represent an oxygen atom,
- R 7 preferably denotes a hydrogen atom or a methyl group
- R 8 preferably denotes a hydrogen atom or a fluorine atom
- R 9 preferably denotes a hydrogen atom, a hydroxyl, a methyl group, a fluorine or chlorine atom
- R 10 preferably denotes a hydrogen atom, a methyl, formyl or a nitrile group
- R 11 preferably denotes a hydrogen atom or a methyl group
- R 12 preferably represents a hydrogen atom, a hydroxymethyl or formyl group
- R 13 and R 14 preferably together represent a thiirane ring, a [2,3c] oxadiazole, a [3,2c] isooxazal ring or a [3,2c ] Pyrazole ring
- Y preferably represents an oxygen atom.
- STEROID stands for a steroidal ring system of sub-formula A, preferably means
- R 1 is a methyl group
- R 6 is a fluorine, chlorine, bromine atom, a trifluoromethyl or a hydroxy group
- R 7 is a methyl group
- R 8 is a fluorine atom and / or
- R 9 is a hydroxy group.
- STEROID stands for a steroidal ring system of sub-formula B, preferably means
- R 1 is a methyl group
- R 6 is a fluorine, chlorine, bromine atom, a trifluoromethyl or a hydroxy group
- R 7 is a methyl group and / or
- R 9 is a hydroxy group.
- STEROID stands for a ring system of sub-formula C, preferably means
- R 6 is a fluorine, chlorine, bromine atom, a trifluoromethyl or a hydroxy group
- R 7 is a methyl group
- R 9 is a hydroxy group and / or
- R 12 is a hydroxymethyl or formyl group.
- STEROID stands for a ring system of sub-formula D, means
- R 1 is a methyl group
- R 6 is a fluorine, chlorine, bromine atom, a trifluoromethyl or a hydroxy group
- R 7 is a methyl group and / or
- Y is an oxygen atom
- STEROID stands for a ring system of sub-formula E, preferably means
- R 1 is a methyl group and / or
- R 9 is a hydroxy group. Particularly preferred compounds are listed below:
- the compounds according to the invention have androgenic activity in vitro and also in vivo (Hershberger test on rats).
- the receptor binding affinities on the androgen receptor listed below illustrate the in vitro activity.
- the receptor binding affinity was determined by competitive binding of a specifically binding 3H-labeled hormone (tracer) and the compound to be tested
- Receptors in the cytosol from animal target organs Receptor saturation and
- the D-homo-17-chloro-16 (17) -en steroids according to the invention advantageously have a very high binding affinity for the androgen receptor.
- the present invention therefore also relates to pharmaceutical compositions which contain at least one D-homo-17-chloro-16 (17) -en steroid of the general formula (I) or its salt, optionally together with pharmaceutically acceptable auxiliaries and carriers.
- These pharmaceutical compositions and medicaments can be intended for oral, rectal, vaginal, subcutaneous, percutaneous, transdermal, buccal, intravenous or intramuscular application.
- conventional carriers and / or diluents they contain at least one compound of the general formula I or its salt.
- the pharmaceuticals according to the present invention are produced in a known manner with the usual solid or liquid carriers or diluents and the commonly used pharmaceutical-technical auxiliaries according to the desired type of application with a suitable dosage.
- the preferred preparations are in a dosage form which is suitable for oral administration. Dosage forms of this type are, for example, tablets, film-coated tablets, coated tablets, capsules, pills, plasters, powders, solutions or suspensions or even depot forms.
- parenteral preparations such as injection solutions are also suitable.
- Suppositories and agents for vaginal use may also be mentioned as preparations.
- Corresponding tablets can be obtained, for example, by mixing the active ingredient with known auxiliaries, for example inert diluents such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc and / or agents for achieving one Depot effects such as carboxylpolymethylene, carboxylmethyl cellulose, cellulose acetate phthalate or polyvinyl acetate can be obtained.
- the tablets can also consist of several layers.
- Coated tablets can accordingly be produced by coating cores produced analogously to the tablets with agents conventionally used in tablet coatings, for example polyvinylpyrrolidone or shellac, gum arabic, talc, titanium oxide or sugar.
- the coated tablet can also consist of several layers, wherein the auxiliaries mentioned above for the tablets can be used.
- Solutions or suspensions with the compounds of general formula I according to the invention can additionally taste-improving agents such as saccharin, cyclamate or sugar and z.
- B. contain flavorings such as vanillin or orange extract. They can also contain suspending agents such as sodium carboxymethyl cellulose or preservatives such as p-hydroxybenzoates.
- Capsules containing the compounds of general formula I can be prepared, for example, by mixing the compound (s) of general formula I with an inert carrier such as milk sugar or sorbitol and encapsulating them in gelatin capsules.
- Suitable suppositories can be produced, for example, by mixing them with suitable carriers such as neutral fats or polyethylene glycol or their derivatives.
- Known basic steroid bodies can be used to prepare the compounds of the general formula I with the partial structures A-F.
- the following steroid bodies can be used, for example:
- dichlorocarbene can be obtained from chloroform by treatment with bases such as, for example, potassium hydroxide or from the sodium salt of trichloroacetic acid by heating in a suitable solvent, such as, for example, Tetrachlorethylene or chloroform, advantageously with the addition of a phase transfer catalyst.
- bases such as, for example, potassium hydroxide or from the sodium salt of trichloroacetic acid by heating in a suitable solvent, such as, for example, Tetrachlorethylene or chloroform, advantageously with the addition of a phase transfer catalyst.
- a suitable solvent such as, for example, Tetrachlorethylene or chloroform
- inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid
- organic acids include acetic acid, propionic acid, maleic acid, fumaric acid, succinic acid, benzoic acid, ascorbic acid, oxalic acid, Salicylic acid, tartaric acid, citric acid, lactic acid, malic acid, mandelic acid, cinnamic acid and methanesulfonic acid.
- 6-methoxy-3,5-cycIo-17 - [(trimethylsilyl) oxy] -androstan-16-ene is refluxed in 400 ml of chloroform with 141 g of trichloroacetic acid sodium salt and 3.3 g of benzyltriethylammonium chloride for 2 hours. It is poured into 1 l of saturated sodium bicarbonate solution, worked up extractively with chloroform and the residue is chromatographed on silica gel for purification. 17-Chloro-6-methoxy-3,5-cyclo-17a-homo-androstan-16-ene-17a-one is obtained.
- 17ass acetoxy-17-chloro-6-methoxy-3,5-cyclo-17a-homoandrostan-16-ene are refluxed in 200 ml of acetone, 21 ml of water and 6 ml of 60% perchloric acid for 1 hour. Then it is neutralized with 10% sodium hydrogen carbonate solution and concentrated. The residue is worked up extractively with ethyl acetate. After concentrating the organic extract, 17ass-acetoxy-17-chloro-17a-homoandrost-5,16-dien-3ß-ol is obtained, which is processed directly.
- methyl magnesium iodide prepared from 2.5 g of magnesium and 6.4 ml of methyl iodide in 80 ml of diethyl ether
- the mixture is cooled to -5 ° C. and 1 g of copper acetate monohydrate (dissolved in 50 ml of THF ) too. It is cooled to -20 ° C. and then a solution of 5 g of 17-chloro-17ass-hydroxy-17a-homoandrost ⁇ 4,6,16 ⁇ trien-3 ⁇ one in 80 ml THF is added dropwise.
- 17-chloro-17ass-hydroxy-17a-homo-estra-4,6,16-trien-3-one can easily be made from 17-chloro-17ass-hydroxy-17a ⁇ homo-estra-4,16-diene-3- on by the method of JA Campbell et al (Steroids 1963, 317). Stage 2 17-chloro-17ass-hydroxy-7 ⁇ -methyl-17a-homo-estra-4, 16-dien-3-one:
- methyl magnesium iodide prepared from 2.5 g of magnesium and 6.4 ml of methyl iodide in 80 ml of diethyl ether
- the mixture is cooled to -5 ° C. and 1 g of copper acetate monohydrate (dissolved in 50 ml of THF ) too. It is cooled to -20 ° C. and then a solution of 5 g of 17-chloro-17ass-hydroxy-17a-homo-estr-4,6,16-trien-3-one in 80 ml of THF is added dropwise. After 2 hours, pour on ice water / 2N sulfuric acid and extract with 3 times 80 ml of ethyl acetate.
- 17-Di - (trimethylsilyloxy) -5 ⁇ -H-androst-16-ene is refluxed in 400 ml of chloroform with 47 g of tnchloroacetic acid sodium salt and 1.1 g of benzyltriethylammonium chloride for 2 hours. It is poured into 300 ml of saturated sodium bicarbonate solution, worked up extractively with chloroform and the residue is chromatographed on silica gel for purification. 17-Chloro-3 ⁇ -trimethylsilyloxy -17a-homo-5 ⁇ -H-androst-16-en-17-one is obtained.
- the 17-chloro-3ß-acetoxy-17a-homo-5-H-androst-16-en-17ass-ol (5 g) obtained is treated with 3,4-dihydro-2H-pyran in the presence of pyridinium tosylate in 100 ml of dichloromethane transferred to the 17a-tetrahydropyranyl ether and the acetate in the 3ß position is saponified with 5 g of potassium hydroxide in 100 ml of boiling methanol.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA200601842A EA200601842A1 (ru) | 2004-04-08 | 2005-04-07 | D-гомо-17-хлор-16(17)-ен-стероиды |
| CA002563541A CA2563541A1 (en) | 2004-04-08 | 2005-04-07 | D-homo-17-chloro-16(17)ene steroids |
| EP05739526A EP1735331A1 (de) | 2004-04-08 | 2005-04-07 | D-homo-17-chlor-16(17)en steroide |
| MXPA06012849A MXPA06012849A (es) | 2004-04-08 | 2005-04-07 | D-homo-17-cloro-16(17)eno esteroides. |
| AU2005231970A AU2005231970A1 (en) | 2004-04-08 | 2005-04-07 | D-homo-17-chloro-16(17)en steroids |
| NO20065126A NO20065126L (no) | 2004-04-08 | 2006-11-07 | D-homo-17-klor-16(17)-en-steroider. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004018441A DE102004018441B4 (de) | 2004-04-08 | 2004-04-08 | D-Homo-17-chlor-16(17)en Steroide |
| DE102004018441.0 | 2004-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005097819A1 true WO2005097819A1 (de) | 2005-10-20 |
Family
ID=34966688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2005/003792 WO2005097819A1 (de) | 2004-04-08 | 2005-04-07 | D-homo-17-chlor-16(17)en steroide |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1735331A1 (es) |
| KR (1) | KR20070007910A (es) |
| CN (1) | CN1997659A (es) |
| AR (1) | AR048536A1 (es) |
| AU (1) | AU2005231970A1 (es) |
| CA (1) | CA2563541A1 (es) |
| CR (1) | CR8736A (es) |
| DE (1) | DE102004018441B4 (es) |
| EA (1) | EA200601842A1 (es) |
| EC (1) | ECSP066973A (es) |
| GT (1) | GT200500084A (es) |
| MX (1) | MXPA06012849A (es) |
| NO (1) | NO20065126L (es) |
| PA (1) | PA8629401A1 (es) |
| SV (1) | SV2005002076A (es) |
| TW (1) | TW200603812A (es) |
| WO (1) | WO2005097819A1 (es) |
| ZA (1) | ZA200609275B (es) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4788218A (en) * | 1984-05-21 | 1988-11-29 | Sri International | 17 a β-hydroxy-7 α-methyl-d-homo-19-norandrost-4,16-diene-3-one and the 17-esters thereof: methods of preparation and uses |
| WO1992011279A1 (de) * | 1990-12-22 | 1992-07-09 | Schering Aktiengesellschaft Berlin Und Bergkamen | D-HOMO-(16-EN)-11β-ARYL-4-ESTRENE, VERFAHREN ZU IHRER HERSTELLUNG SOWIE DEREN VERWENDUNG ALS ARZNEIMITTEL |
| CN1074910C (zh) * | 1993-08-21 | 2001-11-21 | 雀巢制品公司 | 一种调味品的生产方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10151365A1 (de) * | 2001-10-17 | 2003-04-30 | Schering Ag | 17-Chlor-D-Homosteroide als selektive Estrogenrezeptorantagonisten |
-
2004
- 2004-04-08 DE DE102004018441A patent/DE102004018441B4/de not_active Expired - Fee Related
-
2005
- 2005-04-07 KR KR1020067023253A patent/KR20070007910A/ko not_active Application Discontinuation
- 2005-04-07 CN CNA2005800188931A patent/CN1997659A/zh active Pending
- 2005-04-07 CA CA002563541A patent/CA2563541A1/en not_active Abandoned
- 2005-04-07 EA EA200601842A patent/EA200601842A1/ru unknown
- 2005-04-07 AU AU2005231970A patent/AU2005231970A1/en not_active Abandoned
- 2005-04-07 EP EP05739526A patent/EP1735331A1/de not_active Withdrawn
- 2005-04-07 SV SV2005002076A patent/SV2005002076A/es not_active Application Discontinuation
- 2005-04-07 MX MXPA06012849A patent/MXPA06012849A/es unknown
- 2005-04-07 GT GT200500084A patent/GT200500084A/es unknown
- 2005-04-07 TW TW094111013A patent/TW200603812A/zh unknown
- 2005-04-07 WO PCT/EP2005/003792 patent/WO2005097819A1/de active Application Filing
- 2005-04-08 PA PA20058629401A patent/PA8629401A1/es unknown
- 2005-04-08 AR ARP050101392A patent/AR048536A1/es not_active Application Discontinuation
-
2006
- 2006-11-07 ZA ZA200609275A patent/ZA200609275B/xx unknown
- 2006-11-07 CR CR8736A patent/CR8736A/es unknown
- 2006-11-07 NO NO20065126A patent/NO20065126L/no not_active Application Discontinuation
- 2006-11-08 EC EC2006006973A patent/ECSP066973A/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4788218A (en) * | 1984-05-21 | 1988-11-29 | Sri International | 17 a β-hydroxy-7 α-methyl-d-homo-19-norandrost-4,16-diene-3-one and the 17-esters thereof: methods of preparation and uses |
| WO1992011279A1 (de) * | 1990-12-22 | 1992-07-09 | Schering Aktiengesellschaft Berlin Und Bergkamen | D-HOMO-(16-EN)-11β-ARYL-4-ESTRENE, VERFAHREN ZU IHRER HERSTELLUNG SOWIE DEREN VERWENDUNG ALS ARZNEIMITTEL |
| CN1074910C (zh) * | 1993-08-21 | 2001-11-21 | 雀巢制品公司 | 一种调味品的生产方法 |
Non-Patent Citations (3)
| Title |
|---|
| AVERY M A ET AL: "Synthesis and testing of 17a.beta.-hydroxy-7.alpha.-methyl-D-homoestr a-4,16-dien-3-one: a highly potent orally active androgen", STEROIDS: STRUCTURE, FUNCTION, AND REGULATION, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 55, no. 2, February 1990 (1990-02-01), pages 59 - 64, XP002118688, ISSN: 0039-128X * |
| DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; "Preparation of 11.beta.-aryl-D-homoestra-4,16-dienes as contraceptives", XP002341061, retrieved from STN Database accession no. 1994:323998 * |
| DATABASE EPODOC EUROPEAN PATENT OFFICE, THE HAGUE, NL; XP002341062 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE102004018441B4 (de) | 2007-12-20 |
| CN1997659A (zh) | 2007-07-11 |
| NO20065126L (no) | 2007-01-04 |
| CR8736A (es) | 2007-08-28 |
| EP1735331A1 (de) | 2006-12-27 |
| ECSP066973A (es) | 2006-12-29 |
| AR048536A1 (es) | 2006-05-03 |
| PA8629401A1 (es) | 2006-07-03 |
| GT200500084A (es) | 2006-03-24 |
| CA2563541A1 (en) | 2005-10-20 |
| EA200601842A1 (ru) | 2007-04-27 |
| TW200603812A (en) | 2006-02-01 |
| DE102004018441A1 (de) | 2005-11-03 |
| ZA200609275B (en) | 2009-08-26 |
| KR20070007910A (ko) | 2007-01-16 |
| AU2005231970A1 (en) | 2005-10-20 |
| SV2005002076A (es) | 2005-12-06 |
| MXPA06012849A (es) | 2007-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0970103B1 (de) | Antigestagen wirksame steroide mit fluorierter 17alpha-alkylkette | |
| AU628015B2 (en) | 19,11beta-bridged steroids, their production and pharmaceutical preparations containing same | |
| EP0404283B1 (de) | 11-Beta-aryl-4-estrene, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel | |
| EP0254670A1 (de) | 11beta-(4-Isopropenylphenyl)-estra-4,9-diene, deren Herstellung und diese enthaltende pharmazeutische Präparate | |
| EP0277089B1 (de) | 11 Beta-alkinyl-estrene und -estradiene, deren Herstellung und diese enthaltende pharmezeutische Präparate | |
| EP0192598A2 (de) | 11 Beta-N,N-Dimethylaminophenyl-Estradiene, deren Herstellung und diese enthaltende pharmazeutische Präparate | |
| DE10221034A1 (de) | 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln | |
| DE4038128A1 (de) | 8-en-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate | |
| WO1990014354A1 (de) | 9α-HYDROXY-19,11β-ÜBERBRÜCKTE STEROIDE, DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE | |
| DE4042004A1 (de) | 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene | |
| EP1501859B1 (de) | 17a-FLUORALKYL-11BETA-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN | |
| EP1322660B1 (de) | 17alpha-fluoralkylsteroide, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
| EP0567472B1 (de) | D-homo-(16-en)-11 beta-aryl-4-estrene,verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel. | |
| US5446178A (en) | Process for preparing 19,11β-bridged steroids | |
| DE102004018441B4 (de) | D-Homo-17-chlor-16(17)en Steroide | |
| DE3717169A1 (de) | 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate | |
| DE3617883A1 (de) | In 11(beta)-stellung substituierte steroide und verfahren zu deren herstellung | |
| DE3619413A1 (de) | 9(alpha), 10(alpha)-methylen-estrene, deren herstellung und diese enthaltende pharmazeutische praeparate | |
| EP1235850B1 (de) | Ungesättigte 14,15-cyclopropano-androstane, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
| EP1594884B1 (de) | Antitumor wirksame 2-substituierte 18a-homoestra-1,3,5(10)-trien-3-yl sulfamate | |
| WO2005021573A1 (de) | Δ15-d-homosteroide mit androgener wirkung | |
| EP1242445B1 (de) | 14,15-cyclopropanosteroide der 19-norandrostan-reihe, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
| DE10339532A1 (de) | Delta 15-D-Homosteroide mit androgener Wirkung | |
| US20050234111A1 (en) | D-homo-17-chlor-16(17)-ene steroids | |
| EP1165596A1 (de) | 14,15-.alpha.-methylen-equileninderivate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2563541 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12006502080 Country of ref document: PH |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2005739526 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 6278/DELNP/2006 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 06112551 Country of ref document: CO |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/012849 Country of ref document: MX Ref document number: 551108 Country of ref document: NZ Ref document number: 1020067023253 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: CR2006-008736 Country of ref document: CR Ref document number: 2005231970 Country of ref document: AU Ref document number: 200609275 Country of ref document: ZA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200601842 Country of ref document: EA |
|
| ENP | Entry into the national phase |
Ref document number: 2005231970 Country of ref document: AU Date of ref document: 20050407 Kind code of ref document: A |
|
| WWP | Wipo information: published in national office |
Ref document number: 2005231970 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200580018893.1 Country of ref document: CN |
|
| WWP | Wipo information: published in national office |
Ref document number: 2005739526 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1020067023253 Country of ref document: KR |